Page last updated: 2024-11-04

sb 239063 and Diabetic Neuropathies

sb 239063 has been researched along with Diabetic Neuropathies in 2 studies

SB 239063: structure in first source
SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.

Diabetic Neuropathies: Peripheral, autonomic, and cranial nerve disorders that are associated with DIABETES MELLITUS. These conditions usually result from diabetic microvascular injury involving small blood vessels that supply nerves (VASA NERVORUM). Relatively common conditions which may be associated with diabetic neuropathy include third nerve palsy (see OCULOMOTOR NERVE DISEASES); MONONEUROPATHY; mononeuropathy multiplex; diabetic amyotrophy; a painful POLYNEUROPATHY; autonomic neuropathy; and thoracoabdominal neuropathy. (From Adams et al., Principles of Neurology, 6th ed, p1325)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (100.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Agthong, S2
Tomlinson, DR2
Price, SA1
Middlemas, AB1

Other Studies

2 other studies available for sb 239063 and Diabetic Neuropathies

ArticleYear
Inhibition of p38 MAP kinase corrects biochemical and neurological deficits in experimental diabetic neuropathy.
    Annals of the New York Academy of Sciences, 2002, Volume: 973

    Topics: Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Disease Models, Animal; Enzyme Inhi

2002
Mitogen-activated protein kinase p38 mediates reduced nerve conduction velocity in experimental diabetic neuropathy: interactions with aldose reductase.
    Diabetes, 2004, Volume: 53, Issue:7

    Topics: Aldehyde Reductase; Animals; Diabetes Mellitus, Experimental; Diabetic Neuropathies; Enzyme Activati

2004